SOX17
Overview
SOX17 encodes a member of the SOX (SRY-related HMG-box) family of transcription factors. In endometrial cancer, SOX17 is recurrently mutated with novel missense variants and functions to mediate beta-catenin degradation, placing it in the WNT/beta-catenin signaling pathway. SOX17 mutations are mutually exclusive with CTNNB1 and KRAS mutations, consistent with its role in the same pathway.
Alterations observed in the corpus
- SOX17 harbors recurrent novel missense mutations Ala96Gly and Ser403Ile in 8% of copy-number-low endometrial tumors; SOX17 mediates beta-catenin degradation and is mutually exclusive with CTNNB1 and KRAS mutations PMID:23636398
Cancer types (linked)
- UCEC: SOX17 missense mutations occur in ~8% of copy-number-low MSS endometrioid endometrial carcinoma; mutually exclusive with CTNNB1 and KRAS PMID:23636398
Co-occurrence and mutual exclusivity
- SOX17 mutations are mutually exclusive with CTNNB1 and KRAS mutations in endometrial cancer, consistent with convergent WNT/beta-catenin pathway activation PMID:23636398
Therapeutic relevance
- SOX17 mutations implicate the WNT/beta-catenin pathway as a potential therapeutic target in copy-number-low endometrial cancers.
Open questions
- The functional consequence of specific SOX17 missense variants (Ala96Gly, Ser403Ile) on beta-catenin degradation activity requires experimental validation.
Sources
This page was processed by crosslinker on 2026-05-09.